HB2200 (2023 Regular Session)

HB2200

Anti-cancer drugs; analyzing current reimbursement, etc., for medical practices that administer.

What is a Close Vote?

02/07/2023 - House: Read third time and passed House (63-Y 35-N)
02/07/2023 - House: VOTE: Passage (63-Y 35-N)